Characteristics of Early Antibody Mediated Rejection in Antibody Incompatible Living Donor Kidney Transplantation

Transpl Int. 2024 Jul 8:37:12942. doi: 10.3389/ti.2024.12942. eCollection 2024.

Abstract

Antibody incompatible transplantation (AIT) may be an only option for highly sensitized patients. Severe form of early antibody mediated rejection (AMR) adversely affects graft survival after AIT. The aim of this study was to identify individuals at risk of AMR. We analyzed 213 living donor AITs performed at our center. Among 120 ABOi, 58 HLAi and 35 DSA + FCXM-negative cases, the rates of early AMR were 6%, 31%, and 9%, respectively (p < 0.001). On multivariate analysis for graft loss, early AMR had a HR of 3.28 (p < 0.001). The HLAi group had worse death-censored graft survival (p = 0.003). In the HLAi group, Patients with aggressive variant AMR (AAMR) had greater percentage of C3d complement fixing DSA, higher baseline class I and total DSA MFI levels and B-cell FCXM RMF. C1q and C3d complement fixing DSA and strong positivity of baseline B- or T-cell FXCM as predictors of AAMR had 100% sensitivity. Early AMR is of significant clinical concern in AIT as it results in poor graft survival and is not well described in literature. An aggressive variant is characterized by massive rise in DSA levels at rejection. Baseline DSA, C1q, and C3d and baseline FCXM values can be used to risk-stratify candidates for AIT.

Keywords: ABOi; AMR; HLAi; kidney transplantation; memory cells.

MeSH terms

  • ABO Blood-Group System / immunology
  • Adult
  • Aged
  • Blood Group Incompatibility / immunology
  • Complement C1q / immunology
  • Complement C3d / immunology
  • Female
  • Graft Rejection* / immunology
  • Graft Survival* / immunology
  • HLA Antigens / immunology
  • Humans
  • Isoantibodies* / blood
  • Isoantibodies* / immunology
  • Kidney Transplantation*
  • Living Donors*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Retrospective Studies

Substances

  • Isoantibodies
  • Complement C1q
  • Complement C3d
  • ABO Blood-Group System
  • HLA Antigens

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.